Colitis – Placebo-controlled

Share on facebook
Share on pinterest
Share on twitter
Share on email
Share on whatsapp
Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.

Brief Report: Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial

Timna Naftali, Lihi Bar-Lev Schleider, Fabiana Scklerovsky Benjaminov, Fred Meir Konikoff, Shelly Tartakover Matalon, Yehuda Ringel

1Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, 4441002, Israel; 2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Soroka University Medical Centre and Faculty of Health Sciences, Ben-Gurion University of the Negev

Cannabis is often used by patients with ulcerative colitis, but controlled studies are few. We aimed to assess the effect of cannabis in improving clinical and inflammatory outcomes in ulcerative colitis patients.

Methods:In a double-blind, randomized, placebo-controlled trial, patients received either cigarettes containing 0.5 g of dried cannabis flowers with80mgTetrahydrocannabinol (THC)or placebo cigarettes for 8 weeks. Parameters of disease including Lichtiger disease activity index, C reactive protein (CRP), calprotectin, Mayo endoscopic score and quality of life (QOL) were assessed before, during and after treatment.

STUDY POPULATION: 32 patients. Mean age was 30 years, 14 (43%) females

STRAIN: About half of the patients received Erez.

RESULTS:

  • Lichtiger index improved in the cannabis group from 10.9 (IQR 9-14) to5 (IQR 1-7), (p<0.000), and in the placebo group from 11 (IQR 9-13) to 8 (IQR 7-10)(p=0.15, p between groups 0.001).
  • QOL improved in the cannabis group from 77±4 to 98±20 (p=0.000) but not in the placebo group (78±3 at week 0 and 78±17 at week 8;p= 0.459; p between groups 0.007).
  • Mayo endoscopic score changed in the cannabis group from 2.13±1 to 1.25±2 (p=0.007) and in the placebo group from 2.15±1to 1.69±1 (p=0.034, p between groups 0.17).

Conclusion: Short term treatment with THC rich cannabis induced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. However, these beneficial clinical effects were not associated with significant anti-inflammatory improvement in the Mayo endoscopic score or laboratory markers for inflammation.

FULL STUDY LINK

Have you liked our facebook page?

Common Questions

Search by Keyword

Recent publications

Ordering Tikun Olam Products

Proudly leading the revolution for modern Cannabis treatment

Related Topics

Treatment of Crohn’s Disease with Cannabis: An Observational StudyIMAJ – The Israel Medical Association Journal, 2011 Timna Naftali 1, Lihi Bar Lev, Doron Yablecovitch, Elisabeth

Tikun Olam is the first supplier of medical cannabis in Israel and known worldwide as a pioneer of modern medical cannabis.Since its establishment in 2006,

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice Inflammopharmacology 2018 Ruth Gallily1, Zhannah Yekhtin1 1The Lautenberg Center

Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy Scientific Reports, 2019 Lihi Bar-Lev Schleider 1,2, Raphael Mechoulam3, Naama Saban2, Gal